NCT02942914 is a Phase 1 clinical trial of LY3209590 in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company.

Who is sponsoring NCT02942914?

NCT02942914 is sponsored by Eli Lilly and Company.

What drugs are being tested in NCT02942914?

Interventions in NCT02942914: LY3209590, Placebo, Insulin Glargine.

What condition does NCT02942914 study?

NCT02942914 studies Diabetes Mellitus, Type 2.

Is NCT02942914 still recruiting?

NCT02942914 is currently completed. Last updated 7 November 2017.

Last reviewed 2017-11-07 · How we verify

NCT02942914

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of LY3209590 in Healthy Participants and Participants With Type 2 Diabetes

Completed Phase 1 Last updated 7 November 2017

What this trial tests

Phase 1 trial testing LY3209590 in Diabetes Mellitus, Type 2 in 80 participants. Completed in 18 October 2017.

Timeline

20 December 2016

Primary endpoint
18 October 2017

18 October 2017

Quick facts

Lead sponsor	Eli Lilly and Company
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	basic science
Enrollment	80
Start date	20 December 2016
Primary completion	18 October 2017
Estimated completion	18 October 2017
Sites	1 location across Germany

Drugs / interventions tested

LY3209590 — full drug profile →
Placebo
Insulin Glargine (INSULIN GLARGINE) — full drug profile →

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Eli Lilly and Company — full company profile →

Who can join

Adults 18 to 65, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is conducted to evaluate the safety of a study drug given by injection under the skin to healthy participants and participants with type 2 diabetes. It will also investigate how the body processes the study drug and the effect of the study drug on blood sugar levels. Information about any side effects and tolerability will be documented. This study is approximately 30 days for each participant, not including screening. Screening is required within 28 days prior to the start of the study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of LY3209590

Trials testing the same drug.

NCT06362265 — A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus · Phase 1 · completed
NCT06169982 — A Multiple Dose Study of LY3209590 in Participants With Type 2 Diabetes · Phase 1 · completed
NCT05596747 — A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus · Phase 1 · completed
NCT04957914 — A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus · Phase 1 · completed
NCT04768842 — A Study of Two Different Formulations of LY3209590 in Healthy Participants · Phase 1 · completed

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other Eli Lilly and Company trials

Trials by the same sponsor.

NCT07533006 — A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss) · Phase 2 · not yet recruiting
NCT07533019 — A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo · Phase 2 · not yet recruiting
NCT07247357 — A Study of LY4064809 in Healthy Adult Chinese Participants · Phase 1 · completed
NCT07124013 — A Study of Olomorasib (LY3537982) in Healthy Japanese Participants · Phase 1 · completed
NCT07030127 — A Study of LY3985863 in Healthy Participants · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02942914 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eli Lilly and Company
Last refreshed: 7 November 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02942914.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing